PGD2 is the major prostanoid released by activated mast cells and is an important proinflammatory mediator in allergic asthma acting through the CRTh2 receptor. QAW039 is an oral, selective, competitive and reversible CRTh2 antagonist currently in clinical development for treatment of asthma. This study describes the detailed investigation of the receptor binding kinetics of QAW039 and compares it to several other known CRTh2 antagonists.
|Number of pages
|Published - 2014
|Pharmacology 2014 - Queen Elizabeth II Conference Centre, London, United Kingdom
Duration: 1 Dec 2014 → …
|1/12/14 → …